We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Theraclion SA (ALTHE) EUR0.05

Sell:€0.38 Buy:€0.38 Change: €0.01 (2.60%)
Market closed |  Prices as at close on 8 November 2024 | Switch to live prices |
Sell:€0.38
Buy:€0.38
Change: €0.01 (2.60%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 8 November 2024 | Switch to live prices |
Sell:€0.38
Buy:€0.38
Change: €0.01 (2.60%)
Market closed |  Prices as at close on 8 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Theraclion SA is a France-based company, which develops High Intensity Focused Ultrasound (HiFu) machines. The Company is a a spin-off of Inserm and EDAPTechomed. The main activity of the Company is developping, manufacturing and marketing echotherapy medical equipments associating therapy by focused ultrasound and monitoring by ultrasound. The Company provides Echopulse, a device for the non-invasive and outpatient treatment of the fibroadenoma of the breast and thyroid nodules.

Contact details

Address:
244, avenue Pierre Brossolette
MALAKOFF
92240
France
Telephone:
+33 (1) 55489070
Website:
https://www.theraclion.fr/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ALTHE
ISIN:
FR0010120402
Market cap:
€17.74 million
Shares in issue:
45.68 million
Sector:
Health Care Equipment
Exchange:
Euronext Paris
Country:
France
Currency:
Euro
Indices:
n/a

Key personnel

  • Yann Duchesne
    Executive Chairman of the Board
  • Martin Deterre
    Chief Executive Officer
  • David Auregan
    Deputy Chief Executive Officer, Deputy General Manager, Executive Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.